Atrium TherapeuticsRNA +0.16%12 PB Ratio is 0.94 as of Jun. 25, 2026, which is 4% below its 10-year median of 0.98. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,233 Biotechnology companies, Atrium Therapeutics ranks better than 84.51% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Atrium Therapeutics PB Ratio Related Terms
Atrium Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Atrium Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atrium Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrium Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Atrium Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Atrium Therapeutics (RNA) has a PB Ratio of 0.94 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Atrium Therapeutics and its competitors. This is near median its historical median of 0.98. Over the past decade, Atrium Therapeutics' PB Ratio has ranged from 0.86 to 1.22. According to the industry distribution chart, Atrium Therapeutics ranks #191 out of 1233 companies in the Biotechnology industry, placing it in the top 15.5%.
Is Atrium Therapeutics' PB Ratio too high?
Atrium Therapeutics' current PB Ratio of 0.94 is near median its 10-year median of 0.98. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 1.22. The Biotechnology industry median PB Ratio is 2.83. Atrium Therapeutics' value of 0.94 is 66.8% below this industry median. Based on the distribution chart, Atrium Therapeutics ranks #191 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' PB Ratio compare to RNAC and KROS?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #191 out of 1233 companies for PB Ratio. This places Atrium Therapeutics in the top 16% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.83. Atrium Therapeutics' value of 0.94 is 66.8% below this benchmark. Historically, Atrium Therapeutics' own PB Ratio has ranged from 0.86 to 1.22 over the past decade. While the company's 10-year median is 0.98 vs. the industry median of 2.83, Atrium Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atrium Therapeutics's current PB Ratio of 0.94 is 66.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Atrium Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrium Therapeutics's current PB Ratio is 0.94, which is near median its own 10-year median of 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current PB Ratio of 0.94. The current PB Ratio is 0.94, which is near median its 10-year median of 0.98 and 66.8% below the Biotechnology industry median of 2.83. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current PB Ratio is 0.94 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score
Get the complete analysis for RNA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNA has been successfully added to your 